Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Su Yung‐Yeh, Chiara Pircher et al.|Liver International|2025Cited by 10
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The <scp>MAGIC</scp> ‐D IndexMara Persano, Lorenzo Fornaro, Margherita Rimini et al.|Liver International|2025Cited by 9
Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide populationFederica Lo Prinzi, L. Bartalini, Francesca Salani et al.|International Journal of Cancer|2025Cited by 4
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational studyMargherita Rimini, Daniele Lavacchi, Lorenzo Fornaro et al.|International Journal of Cancer|2025Cited by 4
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and DurvalumabMargherita Rimini, Gian Paolo Spinelli, Angela Lamarca et al.|International Journal of Cancer|2026Cited by 0